Two first-in-human, open-label dose-escalation trials of a monoclonal antibody against IL-9, MEDI-528, in normal subjects and subjects with mild asthma have been successfully completed, showing some evidence of efficacy (Parker et al., 2011). Here, IL9 is linked to asthma.